Merck Announces Major Investment in Virginia Pharmaceutical Facility
During a segment on “Morning with Maria,” Peter Navarro, the White House Trade and Manufacturing Counselor, discussed how President Donald Trump’s tariffs aim to diminish U.S. reliance on China, revitalize supply chains, and strengthen national security by enforcing stricter trade regulations.
On Monday, Merck held a groundbreaking ceremony for a new pharmaceutical manufacturing plant in Elkton, Virginia, marking a significant element of the company’s ambitious $70 billion investment plan in the U.S.
The facility will span 400,000 square feet and is projected to generate around 500 permanent jobs once it’s operational, in addition to about 8,000 jobs during its construction phase.
This move by Merck is one of the largest pharmaceutical investments during President Trump’s second term, reflecting the administration’s focus on manufacturing drugs domestically and curbing dependence on foreign production.
Sanat Chattopadhyay, Merck’s executive vice president and head of manufacturing, emphasized the company’s commitment to innovation and serving its customers through domestic manufacturing. “We continue to work collaboratively with the U.S. government to ensure that we remain a key innovation leader in the United States,” he noted.
Eli Lilly to Invest $5 Billion in Virginia Plant Amid Threat of Trump’s Drug Tariffs
The new plant aims to boost domestic production of vaccines and essential pharmaceuticals, focusing on manufacturing and testing capabilities for active ingredients and new small molecules. Merck executives believe this facility will become a vital hub for developing next-generation therapeutics, building on the company’s existing oncology and vaccine offerings.
CEO Robert Davis described the development as a significant milestone for Merck and the American manufacturing landscape, stating, “This investment will help advance our goal of providing new and innovative treatment options to people facing serious health challenges in the United States and globally.”
This announcement aligns with the White House’s initiative to promote “Made in America” medicines.
President Trump Aims to Bring Prescription Drugs Back to the U.S. in Deal with Walmart
In an interview with FOX Business’ Maria Bartiromo, President Trump shared his views, asserting, “The medicines are coming back.” He highlighted that 90% of the essential medications and ingredients are currently sourced from China.
Trump believes that the new tariffs are instrumental in encouraging U.S. production. “We’re going to put tariffs on medical supplies. Unless we make them here, they’re all going to come back,” he remarked.
Merck’s expansion in Elkton represents the company’s fourth major manufacturing initiative in the U.S. this year, with similar projects ongoing in Delaware, North Carolina, and Kansas.
Johnson & Johnson Invests $2 Billion in U.S. Manufacturing, Creating New Jobs
With Merck’s expansion plans combined, over 48,000 construction jobs are anticipated by 2029.
According to Dave Moraldo, Merck’s senior vice president for human health manufacturing, the bulk of construction is expected to wrap up between now and 2028, with manufacturing set to commence in 2029 and supply operations in 2030.
VIEW MERCK’S STOCK PERFORMANCE
Moraldo expressed his eagerness to collaborate with the Trump administration on fostering policies that encourage innovation, positioning the U.S. pharmaceutical sector as a global hub for biopharmaceutical advancements.
Virginia Governor Glenn Youngkin praised the initiative as a major advancement for the state’s life sciences sector, reinforcing Virginia’s status as a leader in advanced manufacturing and medical innovation.
